Evaluation of riboflavin photochemical treatment for inactivation of HCT116 tumor cells mixed in simulative intraoperative salvage blood.

Szczegóły
Abstrakt

Tytuł:: Evaluation of riboflavin photochemical treatment for inactivation of HCT116 tumor cells mixed in simulative intraoperative salvage blood.
Autorzy:: Yu Y; The Medical School of Chinese PLA, Beijing, China.; Department of Blood Transfusion, First Medical Center of Chinese PLA General Hospital, Beijing, China.
Yang L; Department of Blood Transfusion, First Medical Center of Chinese PLA General Hospital, Beijing, China.
He C; Department of Blood Transfusion, First Medical Center of Chinese PLA General Hospital, Beijing, China.
Tai S; Department of Blood Transfusion, First Medical Center of Chinese PLA General Hospital, Beijing, China.
Ma C; Department of Blood Transfusion, First Medical Center of Chinese PLA General Hospital, Beijing, China.
Yang T; Department of Blood Transfusion, First Medical Center of Chinese PLA General Hospital, Beijing, China.
Wang D; The Medical School of Chinese PLA, Beijing, China.; Department of Blood Transfusion, First Medical Center of Chinese PLA General Hospital, Beijing, China.
Źródło:: Transfusion [Transfusion] 2019 Oct; Vol. 59 (10), pp. 3205-3213. Date of Electronic Publication: 2019 Sep 30.
Typ publikacji:: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: Arlington, Va. : American Association Of Blood Banks
MeSH Terms:: Disinfection*
Operative Blood Salvage*
Apoptosis/*drug effects
Erythrocytes/*metabolism
Riboflavin/*pharmacology
HCT116 Cells ; Humans
References:: Paediatr Anaesth. 2015 Mar;25(3):258-64. (PMID: 25267461)
Transfus Med Hemother. 2011;38(1):8-18. (PMID: 21779202)
Liver Transpl. 2005 Mar;11(3):331-5. (PMID: 15719385)
Transfusion. 1999 Jun;39(6):608-15. (PMID: 10378841)
Chest. 2003 Jul;124(1):102-7. (PMID: 12853510)
Int J Radiat Biol. 1989 Nov;56(5):725-37. (PMID: 2573670)
Asian Spine J. 2013 Sep;7(3):167-72. (PMID: 24066210)
Transfusion. 2013 Feb;53(2):373-81. (PMID: 22612327)
Vox Sang. 1997;72(4):221-4. (PMID: 9228711)
J Cardiothorac Surg. 2014 May 14;9:86. (PMID: 24886505)
Vox Sang. 2004 Oct;87(3):173-81. (PMID: 15569069)
Cancer Immunol Immunother. 2004 Oct;53(10):844-54. (PMID: 15197495)
JAMA. 1975 Feb 3;231(5):490-1. (PMID: 1172829)
Front Biosci. 2002 Apr 01;7:c44-62. (PMID: 11915860)
Anaesthesia. 2008 Dec;63(12):1332-8. (PMID: 19032302)
Vox Sang. 2005 Aug;89(2):81-5. (PMID: 16101688)
Biologicals. 2010 Jan;38(1):20-30. (PMID: 20093041)
World J Surg. 2007 Oct;31(10):2044-51. (PMID: 17671807)
Lancet Oncol. 2014 Jan;15(1):e33-41. (PMID: 24384492)
Vox Sang. 2017 Aug;112(6):499-510. (PMID: 28580663)
Vox Sang. 2001;81(2):113-8. (PMID: 11555471)
Br J Surg. 1991 Jun;78(6):713-5. (PMID: 2070241)
Ann Surg. 2016 Aug;264(2):339-43. (PMID: 26501715)
PLoS One. 2015 Jun 22;10(6):e0130864. (PMID: 26098626)
Transfus Apher Sci. 2002 Oct;27(2):153-7. (PMID: 12350050)
Transfusion. 1993 Feb;33(2):128-33. (PMID: 8430451)
J Photochem Photobiol B. 2019 Jul;196:111496. (PMID: 31129507)
Lab Anim Sci. 1993 Apr;43(2):139-46. (PMID: 8320961)
Transfus Med. 2006 Jun;16(3):213-4; author reply 215-6. (PMID: 16764603)
Transplantation. 2008 Mar 27;85(6):863-9. (PMID: 18360269)
Spine J. 2017 Jul;17(7):977-982. (PMID: 28323241)
Int J Radiat Biol. 1989 Nov;56(5):553-60. (PMID: 2573646)
Transfusion. 2013 Dec;53(12):3174-83. (PMID: 23656538)
Transpl Int. 2013 Jan;26(1):84-9. (PMID: 23194351)
Transfus Med. 2004 Apr;14(2):151-5. (PMID: 15113379)
Substance Nomenclature:: TLM2976OFR (Riboflavin)
Entry Date(s):: Date Created: 20191002 Date Completed: 20200609 Latest Revision: 20200609
Update Code:: 20240105
PubMed Central ID:: PMC6856795
DOI:: 10.1111/trf.15499
PMID:: 31571260
: Czasopismo naukowe

Full Text Finder

Background: Radiation and filtration have achieved satisfactory results in inactivation or removal of tumor cells mixed in salvage blood, but some drawbacks remain. This study evaluated the inactivation on HCT116 cells mixed in simulative salvage blood by riboflavin photochemical treatment.
Methods: HCT116 cells were added to the whole blood to simulate contaminated salvaged blood. The mixed blood was added with riboflavin of 50 μmol/L final concentration and illuminated by ultraviolet light. The samples were divided into control group and Experimental Groups 1 (18 J/cm 2 ), 2 (23.4 J/cm 2 ), and 3 (28.8 J/cm 2 ). An autotransfusion system (Cell Saver Elite, Haemonetics) was used to simulate the intraoperative blood salvage procedure to deal with whole blood. The apoptosis rate and tumorigenicity of HCT116 cells and the superimposed damage to red blood cells (RBCs) were evaluated.
Results: The apoptosis rates of HCT116 in Experimental Groups 1, 2, and 3 were much higher than that in the control group. Tumor growth was found in the control group, but no tumor growth was found in the three experimental groups. The hemolysis rates in the three experimental groups were significantly higher than that in the control group, but much lower than the quality standard of RBCs at the end of preservation. The concentration of adenosine triphosphate in RBCs was comparable in the control and experimental groups.
Conclusion: Riboflavin at a 50 μmol/L final concentration and 18 J/cm 2 ultraviolet illumination can effectively inactivate HCT116 cells in salvaged blood, with minimum damage to the structure and function of RBCs, and the main quality indexes of salvaged RBCs were within the standard range.
(© 2019 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.)

Informacja